Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 465

1.

Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals.

Lodi S, Günthard HF, Gill J, Phillips AN, Dunn D, Vu Q, Siemieniuk R, Garcia F, Logan R, Jose S, Bucher HC, Scherrer AU, Reiss P, van Sighem A, Boender TS, Porter K, Gilson R, Paraskevis D, Simeon M, Vourli G, Moreno S, Jarrin I, Sabin C, Hernán MA.

J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):314-320. doi: 10.1097/QAI.0000000000002135.

PMID:
31609929
2.

Pilot phase of an internet-based RCT of HIVST targeting MSM and transgender people in England and Wales: advertising strategies and acceptability of the intervention.

Witzel TC, Gabriel MM, McCabe L, Weatherburn P, Gafos M, Speakman A, Pebody R, Burns FM, Bonell C, Lampe FC, Dunn DT, Ward D, Harbottle J, Phillips AN, McCormack S, Rodger AJ.

BMC Infect Dis. 2019 Aug 8;19(1):699. doi: 10.1186/s12879-019-4247-1.

3.

Strengthening the scale-up and uptake of effective interventions for sex workers for population impact in Zimbabwe.

Cowan FM, Chabata ST, Musemburi S, Fearon E, Davey C, Ndori-Mharadze T, Bansi-Matharu L, Cambiano V, Steen R, Busza J, Yekeye R, Mugurungi O, Hargreaves JR, Phillips AN.

J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25320. doi: 10.1002/jia2.25320.

4.

Cost-per-diagnosis as a metric for monitoring cost-effectiveness of HIV testing programmes in low-income settings in southern Africa: health economic and modelling analysis.

Phillips AN, Cambiano V, Nakagawa F, Bansi-Matharu L, Wilson D, Jani I, Apollo T, Sculpher M, Hallett T, Kerr C, van Oosterhout JJ, Eaton JW, Estill J, Williams B, Doi N, Cowan F, Keiser O, Ford D, Hatzold K, Barnabas R, Ayles H, Meyer-Rath G, Nelson L, Johnson C, Baggaley R, Fakoya A, Jahn A, Revill P.

J Int AIDS Soc. 2019 Jul;22(7):e25325. doi: 10.1002/jia2.25325.

5.

Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study.

Castillo-Mancilla JR, Phillips AN, Neaton JD, Neuhaus J, Sharma S, Baker JV, Collins S, Mannheimer S, Pett S, Touzeau-Römer V, Polizzotto MN, Lundgren JD, Gardner EM; INSIGHT START Study Group.

J Int AIDS Soc. 2019 Jun;22(6):e25297. doi: 10.1002/jia2.25297.

6.

Enhancing national prevention and treatment services for sex workers in Zimbabwe: a process evaluation of the SAPPH-IRe trial.

Busza J, Chiyaka T, Musemburi S, Fearon E, Davey C, Chabata S, Mushati P, Dirawo J, Napierala S, Phillips AN, Cowan FM, Hargreaves JR.

Health Policy Plan. 2019 Jun 1;34(5):337-345. doi: 10.1093/heapol/czz037.

PMID:
31157368
7.

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.

Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Raben D, Coll P, Antinori A, Nwokolo N, Rieger A, Prins JM, Blaxhult A, Weber R, Van Eeden A, Brockmeyer NH, Clarke A, Del Romero Guerrero J, Raffi F, Bogner JR, Wandeler G, Gerstoft J, Gutiérrez F, Brinkman K, Kitchen M, Ostergaard L, Leon A, Ristola M, Jessen H, Stellbrink HJ, Phillips AN, Lundgren J; PARTNER Study Group.

Lancet. 2019 Jun 15;393(10189):2428-2438. doi: 10.1016/S0140-6736(19)30418-0. Epub 2019 May 2.

8.

Intimate partner violence, depression, and sexual behaviour among gay, bisexual and other men who have sex with men in the PROUD trial.

Miltz AR, Lampe FC, Bacchus LJ, McCormack S, Dunn D, White E, Rodger A, Phillips AN, Sherr L, Clarke A, McOwan A, Sullivan A, Gafos M.

BMC Public Health. 2019 Apr 25;19(1):431. doi: 10.1186/s12889-019-6757-6.

9.

Preferences for HIV testing services among men who have sex with men in the UK: A discrete choice experiment.

Miners A, Nadarzynski T, Witzel C, Phillips AN, Cambiano V, Rodger AJ, Llewellyn CD.

PLoS Med. 2019 Apr 11;16(4):e1002779. doi: 10.1371/journal.pmed.1002779. eCollection 2019 Apr.

10.

Challenges in modelling the proportion of undiagnosed HIV infections in Sweden.

Andersson E, Nakagawa F, van Sighem A, Axelsson M, Phillips AN, Sönnerborg A, Albert J.

Euro Surveill. 2019 Apr;24(14). doi: 10.2807/1560-7917.ES.2019.24.14.1800203.

11.

Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiators.

Bansi-Matharu L, Rodriguez Loria G, Cole SR, Mugerwa H, Vecino I, Lundgren J, Pulik P, Smith C, Phillips AN; INSIGHT START Study Group.

AIDS. 2019 Jul 1;33(8):1385-1390. doi: 10.1097/QAD.0000000000002210.

PMID:
30932953
12.

Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa.

Selinger C, Bershteyn A, Dimitrov DT, Adamson BJS, Revill P, Hallett TB, Phillips AN, Bekker LG, Rees H, Gray G.

Vaccine. 2019 Apr 10;37(16):2258-2267. doi: 10.1016/j.vaccine.2019.02.073. Epub 2019 Mar 16.

13.

Associations of depression and anxiety symptoms with sexual behaviour in women and heterosexual men attending sexual health clinics: a cross-sectional study.

Coyle RM, Lampe FC, Miltz AR, Sewell J, Anderson J FRCP, Apea V, Collins S, Dhairyawan R, Johnson AM, Lascar M, Mann S, O'Connell R, Sherr L, Speakman A, Tang A, Phillips AN, Rodger A; AURAH Study Group.

Sex Transm Infect. 2019 Jun;95(4):254-261. doi: 10.1136/sextrans-2018-053689. Epub 2019 Feb 27.

14.

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.

Phillips AN, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A, Lundgren JD, De Luca A, Pillay D, Mellors J, Cambiano V, Bansi-Matharu L, Nakagawa F, Kalua T, Jahn A, Apollo T, Mugurungi O, Clayden P, Gupta RK, Barnabas R, Revill P, Cohn J, Bertagnolio S, Calmy A.

Lancet HIV. 2019 Feb;6(2):e116-e127. doi: 10.1016/S2352-3018(18)30317-5. Epub 2018 Nov 29.

15.

90-90-90 by 2020? Estimation and projection of the adult HIV epidemic and ART programme in Zimbabwe - 2017 to 2020.

Bansi-Matharu L, Cambiano V, Apollo T, Yekeye R, Dirawo J, Musemburi S, Davey C, Napierala S, Fearon E, Mpofu A, Mugurungi O, Hargreaves JR, Cowan FM, Phillips AN.

J Int AIDS Soc. 2018 Nov;21(11):e25205. doi: 10.1002/jia2.25205.

16.

Chronic Kidney Disease Risk in African and Caribbean Populations With HIV.

Jose S, Hamzah L, Jones R, Williams D, Winston A, Burns F, Phillips AN, Sabin CA, Post FA; UK CHIC Study.

J Infect Dis. 2018 Oct 20;218(11):1767-1772. doi: 10.1093/infdis/jiy397.

17.

Associations between serum albumin and serious non-AIDS events among people living with HIV.

Ronit A, Hatleberg CI, Ryom L, Bonnet F, El-Sadr W, Reiss P, Weber R, Pradier C, De Wit S, Law M, d'Arminio Monforte A, Lundgren J, Mocroft A, Phillips AN, Sabin CA; D:A:D Study Group.

AIDS. 2018 Aug 24;32(13):1837-1848. doi: 10.1097/QAD.0000000000001900.

18.

Ethnicity and sexual risk in heterosexual people attending sexual health clinics in England: a cross-sectional, self-administered questionnaire study.

Coyle RM, Miltz AR, Lampe FC, Sewell J, Phillips AN, Speakman A, Dhar J, Sherr L, Sadiq ST, Taylor S, Ivens DR, Collins S, Elford J, Anderson J, Rodger A; AURAH Study Group.

Sex Transm Infect. 2018 Aug;94(5):384-391. doi: 10.1136/sextrans-2017-053308. Epub 2018 Mar 8.

19.

Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study.

Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group.

J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25083.

20.

Association of Suboptimal Antiretroviral Therapy Adherence With Inflammation in Virologically Suppressed Individuals Enrolled in the SMART Study.

Castillo-Mancilla JR, Phillips AN, Neaton JD, Neuhaus J, Collins S, Mannheimer S, Pett S, Touzeau-Römer V, Polizzotto MN, Lundgren JD, Gardner EM; INSIGHT SMART Study Group.

Open Forum Infect Dis. 2017 Dec 22;5(1):ofx275. doi: 10.1093/ofid/ofx275. eCollection 2018 Jan.

21.

Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study.

Ronit A, Sharma S, Baker JV, Mngqibisa R, Delory T, Caldeira L, Ndembi N, Lundgren JD, Phillips AN; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategic Timing of Antiretroviral Treatment (START) Study Group.

J Infect Dis. 2018 Jan 17;217(3):405-412. doi: 10.1093/infdis/jix350.

22.

Effect of population viral load on prospective HIV incidence in a hyperendemic rural African community.

Tanser F, Vandormael A, Cuadros D, Phillips AN, de Oliveira T, Tomita A, Bärnighausen T, Pillay D.

Sci Transl Med. 2017 Dec 13;9(420). pii: eaam8012. doi: 10.1126/scitranslmed.aam8012.

23.

Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion.

Stirrup OT, Copas AJ, Phillips AN, Gill MJ, Geskus RB, Touloumi G, Young J, Bucher HC, Babiker AG; CASCADE Collaboration in EuroCoord.

HIV Med. 2018 Mar;19(3):184-194. doi: 10.1111/hiv.12567. Epub 2017 Dec 1.

24.

The Neural Basis of Changing Social Norms through Persuasion.

Yomogida Y, Matsumoto M, Aoki R, Sugiura A, Phillips AN, Matsumoto K.

Sci Rep. 2017 Nov 24;7(1):16295. doi: 10.1038/s41598-017-16572-2.

25.

Eligibility for PrEP among MSM attending GUM clinics in the UK.

Miltz AR, Cambiano V, Lampe FC, Sewell J, Speakman A, Phillips AN, Ivens DR, Asboe D, Collins S, Brady M, Nwokolo NC, Rodger AJ; AURAH Study Group.

Sex Transm Infect. 2017 Dec;93(8):571. doi: 10.1136/sextrans-2017-053268. No abstract available.

PMID:
29175993
26.

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.

Phillips AN, Cambiano V, Nakagawa F, Revill P, Jordan MR, Hallett TB, Doherty M, De Luca A, Lundgren JD, Mhangara M, Apollo T, Mellors J, Nichols B, Parikh U, Pillay D, Rinke de Wit T, Sigaloff K, Havlir D, Kuritzkes DR, Pozniak A, van de Vijver D, Vitoria M, Wainberg MA, Raizes E, Bertagnolio S; Working Group on Modelling Potential Responses to High Levels of Pre-ART Drug Resistance in Sub-Saharan Africa.

Lancet HIV. 2018 Mar;5(3):e146-e154. doi: 10.1016/S2352-3018(17)30190-X. Epub 2017 Nov 22.

27.

Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance.

Lodi S, Günthard HF, Dunn D, Garcia F, Logan R, Jose S, Bucher HC, Scherrer AU, Schneider MP, Egger M, Glass TR, Reiss P, van Sighem A, Boender TS, Phillips AN, Porter K, Hawkins D, Moreno S, Monge S, Paraskevis D, Simeon M, Vourli G, Sabin C, Hernán MA; HIV-CAUSAL Collaboration.

AIDS. 2018 Jan 28;32(3):327-335. doi: 10.1097/QAD.0000000000001692.

28.

Implications for a policy of initiating antiretroviral therapy in people diagnosed with human immunodeficiency virus: the CAPRA research programme.

Miltz A, Phillips AN, Speakman A, Cambiano V, Rodger A, Lampe FC.

Southampton (UK): NIHR Journals Library; 2017 Oct.

29.

Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.

Cambiano V, Miners A, Dunn D, McCormack S, Ong KJ, Gill ON, Nardone A, Desai M, Field N, Hart G, Delpech V, Cairns G, Rodger A, Phillips AN.

Lancet Infect Dis. 2018 Jan;18(1):85-94. doi: 10.1016/S1473-3099(17)30540-6. Epub 2017 Oct 17.

30.

Abacavir use and risk of recurrent myocardial infarction.

Sabin CA, Ryom L, d'Arminio Monforte A, Hatleberg CI, Pradier C, El-Sadr W, Kirk O, Weber R, Phillips AN, Mocroft A, Bonnet F, Law M, de Wit S, Reiss P, Lundgren JD; D:A:D Study Group.

AIDS. 2018 Jan 2;32(1):79-88. doi: 10.1097/QAD.0000000000001666.

PMID:
29028664
31.

Early virological response to HIV treatment: can we predict who is likely to experience subsequent treatment failure? Results from an observational cohort study, London, UK.

Brima N, Lampe FC, Copas A, Gilson R, Williams I, Johnson MA, Phillips AN, Smith CJ.

J Int AIDS Soc. 2017 Aug 30;20(1):21567. doi: 10.7448/IAS.20.21567.

32.

Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older.

Lodi S, Costagliola D, Sabin C, Del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, Kovari H, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill MJ, Krentz H, Phillips AN, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA.

J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):311-318. doi: 10.1097/QAI.0000000000001498.

33.

Condomless sex in HIV-diagnosed men who have sex with men in the UK: prevalence, correlates, and implications for HIV transmission.

Daskalopoulou M, Rodger AJ, Phillips AN, Sherr L, Elford J, McDonnell J, Edwards S, Perry N, Wilkins E, Collins S, Johnson AM, Burman WJ, Speakman A, Lampe FC; ASTRA Study Group.

Sex Transm Infect. 2017 Dec;93(8):590-598. doi: 10.1136/sextrans-2016-053029. Epub 2017 Jul 5.

34.

The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.

Schultze A, Paredes R, Sabin C, Phillips AN, Pillay D, Mackie N, Castagna A, Chadwick D, Falconer K, Geretti AM, Post FA, Hill T, Kirk O, Pozniak A, Nelson M, Tostevin A, Dunn D, Lundgren J, Cozzi-Lepri A.

Antivir Ther. 2018;23(2):105-116. doi: 10.3851/IMP3178.

PMID:
28627486
35.

Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial.

Baker JV, Sharma S, Achhra AC, Bernardino JI, Bogner JR, Duprez D, Emery S, Gazzard B, Gordin J, Grandits G, Phillips AN, Schwarze S, Soliman EZ, Spector SA, Tambussi G, Lundgren J; INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Treatment) Study Group.

J Am Heart Assoc. 2017 May 22;6(5). pii: e004987. doi: 10.1161/JAHA.116.004987.

36.

Clinically significant depressive symptoms and sexual behaviour among men who have sex with men.

Miltz AR, Rodger AJ, Sewell J, Speakman A, Phillips AN, Sherr L, Gilson RJ, Asboe D, Nwokolo NC, Clarke A, Gompels MM, Allan S, Collins S, Lampe FC; AURAH Study Group.

BJPsych Open. 2017 May 8;3(3):127-137. doi: 10.1192/bjpo.bp.116.003574. eCollection 2017 May.

37.

Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study.

O'Connor J, Smith C, Lampe FC, Johnson MA, Chadwick DR, Nelson M, Dunn D, Winston A, Post FA, Sabin C, Phillips AN; UK Collaborative HIV Cohort (CHIC) Study.

Lancet HIV. 2017 Jul;4(7):e295-e302. doi: 10.1016/S2352-3018(17)30053-X. Epub 2017 May 4.

38.

Impact of decentralisation of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys.

Abongomera G, Kiwuwa-Muyingo S, Revill P, Chiwaula L, Mabugu T, Phillips AN, Katabira E, Chan AK, Gilks C, Musiime V, Hakim J, Kityo C, Colebunders R, Gibb DM, Seeley J, Ford D; Lablite Project Team.

Int Health. 2017 Mar 1;9(2):91-99. doi: 10.1093/inthealth/ihx006.

39.

Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa.

Phillips AN, Stover J, Cambiano V, Nakagawa F, Jordan MR, Pillay D, Doherty M, Revill P, Bertagnolio S.

J Infect Dis. 2017 May 1;215(9):1362-1365. doi: 10.1093/infdis/jix089. Erratum in: J Infect Dis. 2017 Nov 15;216(8):1048.

40.

Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses.

Burch LS, Smith CJ, Anderson J, Sherr L, Rodger AJ, O'Connell R, Geretti AM, Gilson R, Fisher M, Elford J, Jones M, Collins S, Azad Y, Phillips AN, Speakman A, Johnson MA, Lampe FC.

Lancet Public Health. 2016 Nov;1(1):e26-e36. doi: 10.1016/S2468-2667(16)30002-0.

41.

Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinics.

Sewell J, Miltz A, Lampe FC, Cambiano V, Speakman A, Phillips AN, Stuart D, Gilson R, Asboe D, Nwokolo N, Clarke A, Collins S, Hart G, Elford J, Rodger AJ; Attitudes to and Understanding of Risk of Acquisition of HIV (AURAH) Study Group.

Int J Drug Policy. 2017 May;43:33-43. doi: 10.1016/j.drugpo.2017.01.001. Epub 2017 Feb 10.

PMID:
28189979
42.

Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.

O'Connor J, Vjecha MJ, Phillips AN, Angus B, Cooper D, Grinsztejn B, Lopardo G, Das S, Wood R, Wilkin A, Klinker H, Kantipong P, Klingman KL, Jilich D, Herieka E, Denning E, Abubakar I, Gordin F, Lundgren JD; INSIGHT START study group.

Lancet HIV. 2017 Mar;4(3):e105-e112. doi: 10.1016/S2352-3018(16)30216-8. Epub 2017 Jan 5.

43.

Accuracy of self-report of HIV viral load among people with HIV on antiretroviral treatment.

Sewell J, Daskalopoulou M, Nakagawa F, Lampe FC, Edwards S, Perry N, Wilkins E, O'Connell R, Jones M, Collins S, Speakman A, Phillips AN, Rodger AJ; Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) Study Group.

HIV Med. 2017 Aug;18(7):463-473. doi: 10.1111/hiv.12477. Epub 2016 Dec 22.

44.

Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa.

Phillips AN, Cambiano V, Nakagawa F, Bansi-Matharu L, Sow PS, Ehrenkranz P, Ford D, Mugurungi O, Apollo T, Murungu J, Bangsberg DR, Revill P.

PLoS One. 2016 Dec 15;11(12):e0167654. doi: 10.1371/journal.pone.0167654. eCollection 2016.

45.

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK.

El Bouzidi K, White E, Mbisa JL, Sabin CA, Phillips AN, Mackie N, Pozniak AL, Tostevin A, Pillay D, Dunn DT; UK HIV Drug Resistance Database; (UKHDRD) and the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees; UK HIV Drug Resistance Database (UKHDRD) and the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees.

J Antimicrob Chemother. 2016 Dec;71(12):3487-3494. Epub 2016 Sep 28.

46.

An epidemiological modelling study to estimate the composition of HIV-positive populations including migrants from endemic settings.

Nakagawa F; Writing Group on HIV Epidemiologic Estimates in Countries With Migrant Populations From High Prevalence Areas.

AIDS. 2017 Jan 28;31(3):417-425. doi: 10.1097/QAD.0000000000001329.

47.

The per-protocol effect of immediate versus deferred antiretroviral therapy initiation.

Lodi S, Sharma S, Lundgren JD, Phillips AN, Cole SR, Logan R, Agan BK, Babiker A, Klinker H, Chu H, Law M, Neaton JD, Hernán MA; INSIGHT Strategic Timing of AntiRetroviral Treatment (START) study group.

AIDS. 2016 Nov 13;30(17):2659-2663.

48.

Point-of-Care Viral Load Testing for Sub-Saharan Africa: Informing a Target Product Profile.

Phillips AN, Cambiano V, Nakagawa F, Ford D, Apollo T, Murungu J, Rousseau C, Garnett G, Ehrenkranz P, Bansi-Matharu L, Vojnov L, Katz Z, Peeling R, Revill P.

Open Forum Infect Dis. 2016 Jul 29;3(3):ofw161. eCollection 2016 Sep. Erratum in: Open Forum Infect Dis. 2018 Jan 30;5(1):ofx181.

49.

Non-Disclosure of HIV Status and Associations with Psychological Factors, ART Non-Adherence, and Viral Load Non-Suppression Among People Living with HIV in the UK.

Daskalopoulou M, Lampe FC, Sherr L, Phillips AN, Johnson MA, Gilson R, Perry N, Wilkins E, Lascar M, Collins S, Hart G, Speakman A, Rodger AJ; ASTRA Study Group.

AIDS Behav. 2017 Jan;21(1):184-195. doi: 10.1007/s10461-016-1541-4.

50.

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.

Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Asboe D, Viciana P, Gutiérrez F, Clotet B, Pradier C, Gerstoft J, Weber R, Westling K, Wandeler G, Prins JM, Rieger A, Stoeckle M, Kümmerle T, Bini T, Ammassari A, Gilson R, Krznaric I, Ristola M, Zangerle R, Handberg P, Antela A, Allan S, Phillips AN, Lundgren J; PARTNER Study Group.

JAMA. 2016 Jul 12;316(2):171-81. doi: 10.1001/jama.2016.5148. Erratum in: JAMA. 2016 Aug 9;316(6):667. JAMA. 2016 Nov 15;316(19):2048.

PMID:
27404185

Supplemental Content

Loading ...
Support Center